While metformin is the most common treatment of choice in children with type 2 diabetes, early loss of glycemic control has been observed with metformin monotherapy.
Although type 2 diabetes is the leading cause of kidney failure, few long-term treatment options for renoprotection in these patients are currently available.
The American Diabetes Association has updated its 2019 standards of care for diabetes focusing on the improvement of cardiovascular and renal health in individuals with diabetes.
In recognition of the rising prevalence of diabetes in the United States, especially among older adults, the Endocrine Society has published a new clinical practice guideline for the treatment of diabetes...
In a recent study, researchers sought to explore the effects of concomitant use of GLP-1 receptor agonists with SGLT-2 inhibitors in patients with poorly controlled type 2 diabetes.
In a recent study, researchers sought to estimate the long-term risk of cardiovascular disease based on fasting glucose levels that are below the threshold of diabetes.
While it is already known that ideal cardiovascular health is associated with lower risk of diabetes, whether this association persists across glycemic levels is unknown.
The American College of Cardiology has released new guidance on the use of therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
